- Home
- ACET vs ALRN Comparison
ACET vs ALRN Comparison
Compare ACET & ALRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACET
- ALRN
- Stock Information
- Founded
- ACET 1947
- ALRN 2001
- Country
- ACET United States
- ALRN United States
- Employees
- ACET N/A
- ALRN N/A
- Industry
- ACET Biotechnology: Pharmaceutical Preparations
- ALRN Biotechnology: Pharmaceutical Preparations
- Sector
- ACET Health Care
- ALRN Health Care
- Exchange
- ACET Nasdaq
- ALRN Nasdaq
- Market Cap
- ACET 93.1M
- ALRN 76.9M
- IPO Year
- ACET N/A
- ALRN 2017
- Fundamental
- Price
- ACET $0.96
- ALRN $1.92
- Analyst Decision
- ACET Strong Buy
- ALRN Strong Buy
- Analyst Count
- ACET 4
- ALRN 1
- Target Price
- ACET $5.67
- ALRN $19.00
- AVG Volume (30 Days)
- ACET 790.0K
- ALRN 92.8K
- Earning Date
- ACET 11-06-2024
- ALRN 11-14-2024
- Dividend Yield
- ACET N/A
- ALRN N/A
- EPS Growth
- ACET N/A
- ALRN N/A
- EPS
- ACET N/A
- ALRN N/A
- Revenue
- ACET N/A
- ALRN N/A
- Revenue This Year
- ACET N/A
- ALRN N/A
- Revenue Next Year
- ACET N/A
- ALRN N/A
- P/E Ratio
- ACET N/A
- ALRN N/A
- Revenue Growth
- ACET N/A
- ALRN N/A
- 52 Week Low
- ACET $0.89
- ALRN $1.61
- 52 Week High
- ACET $3.77
- ALRN $7.42
- Technical
- Relative Strength Index (RSI)
- ACET 37.36
- ALRN 29.69
- Support Level
- ACET $0.91
- ALRN $1.85
- Resistance Level
- ACET $1.12
- ALRN $2.38
- Average True Range (ATR)
- ACET 0.09
- ALRN 0.30
- MACD
- ACET 0.00
- ALRN -0.01
- Stochastic Oscillator
- ACET 16.21
- ALRN 6.31
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
About ALRN Aileron Therapeutics Inc.
Aileron Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations to reduce or eliminate chemotherapy-induced side effects. The company currently has two product candidates in clinical development, LTI-03 and LTI-01, and multiple candidates in preclinical development focused on fibrosis indications.